Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week Low – Here’s Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price reached a new 52-week low on Tuesday . The stock traded as low as $17.40 and last traded at $17.47, with a volume of 12685 shares trading hands. The stock had previously closed at $18.14.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on DNTH. Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Wedbush reaffirmed an “outperform” rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. TD Cowen started coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They set a “buy” rating on the stock. Guggenheim reissued a “buy” rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $54.33.

Dianthus Therapeutics Price Performance

The company has a market cap of $573.75 million, a P/E ratio of -7.14 and a beta of 1.82. The stock has a fifty day moving average price of $21.68 and a two-hundred day moving average price of $24.04.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $1.33 million for the quarter, compared to analysts’ expectations of $1.40 million. Equities analysts predict that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP boosted its stake in shares of Dianthus Therapeutics by 12.2% in the 4th quarter. Wellington Management Group LLP now owns 60,337 shares of the company’s stock worth $1,315,000 after buying an additional 6,552 shares during the last quarter. Woodline Partners LP boosted its position in Dianthus Therapeutics by 20.0% in the fourth quarter. Woodline Partners LP now owns 300,504 shares of the company’s stock worth $6,551,000 after purchasing an additional 50,000 shares during the last quarter. Vestal Point Capital LP grew its stake in Dianthus Therapeutics by 172.2% in the 4th quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company’s stock valued at $23,435,000 after purchasing an additional 680,000 shares during the period. Octagon Capital Advisors LP increased its position in shares of Dianthus Therapeutics by 20.8% during the 4th quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company’s stock valued at $46,002,000 after purchasing an additional 363,500 shares during the last quarter. Finally, Millennium Management LLC raised its stake in shares of Dianthus Therapeutics by 160.2% during the 4th quarter. Millennium Management LLC now owns 90,436 shares of the company’s stock worth $1,972,000 after purchasing an additional 55,682 shares during the period. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.